BCM
MRTX

BlueCrest Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

BlueCrest Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-7,475
Closed -$582K – 630
2019
Q3 		$582K Buy
+7,475
New +$702K 0.04% 252
2018
Q2 		– Sell
-82,085
Closed -$2.52M – 1908
2018
Q1 		$2.52M Buy
+82,085
New +$2.28M 0.08% 260

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlueCrest Capital Management's MRTX Position: Q4 2019 in Review

BlueCrest Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2019, closing a stake of 7,475 shares — an estimated $582K sold.

BlueCrest Capital Management first reported a position in MRTX in Q1 2018 and held it in 2 quarters. The position peaked at $2.52M in Q1 2018. 190 funds tracked by Wall St. Rank hold MRTX as of Q4 2019.

  • BlueCrest Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 7,475 Mirati Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $582K.
  • BlueCrest Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2018 and held it in 2 quarters.
  • BlueCrest Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $2.52M in Q1 2018.
  • 190 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2019.

Based on BlueCrest Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.